Henry Schein, Inc. provides health care products and services globally, with a market cap of $9.2 billion. The stock has slightly outperformed in 2026, growing 3.5% YTD. However, HSIC has seen no organic revenue growth in recent years, leading to concerns among investors. The stock closed down over 2% after announcing a new CEO. Analysts expect EPS to grow 3.6% YoY to $4.91 for the year ending in December 2025. The consensus rating is a “Moderate Buy” based on 16 analysts, with a mean price target of $78.14. Mizuho Securities maintains a “Hold” rating with a price target of $81.

Read more at Barchart: Henry Schein Stock: Analyst Estimates & Ratings